Tonix Pharmaceuticals Holding Corp.
TNXP · NASDAQ
Market open$12.20$-0.230000 (-1.85%)
Key statistics
Previous close$12.43
Open$12.39
Day high$12.42
Day low$12.08
52-week high$69.97
52-week low$10.03
Market cap194.48M
Volume59.23K
Average volume502.19K
P/E ratio-0.85
Forward P/E—
EPS-14.36
Dividend yield0.00%
Market context
Why it moved
TNXP shares moved notably higher likely driven by speculative retail trading interest and momentum buying, as no specific fundamental catalyst was identified in available news sources for the session.
What is happening
Recent company-specific developments and publisher coverage.
GlobeNewswire · July 15, 2026Tonix Pharmaceuticals Announces Publication in theInvesting.com · June 24, 2026Raymond James initiates Tonix Pharma stock coverage with strong buyGuruFocus · May 11, 2026Tonix Pharmaceuticals (TNXP) Reports Financial Update for Q1 202Stocktwits · May 6, 2026Why TNXP Stock Is Suddenly Back On Retail RadarStocktwits · May 2, 2026TNXP Slips After Hours On Slower Than Expected Launch For Fibromyalgia DrugStocktwits · March 13, 2026TNXP Stock Rises Premarket: Investors Cheer Early Traction For Fibromyalgia Drug Despite Weak Q4 PrintInvesting.com · March 3, 2026Tonix Pharmaceuticals moves to Nasdaq Global Select MarketSeeking Alpha · August 19, 2025Tonix Pharmaceuticals Soars, Then Sinks: What's Next After Tonmya's Approval (Upgrade) Benzinga · July 15, 2026Tonix Pharma Announces Publication Of Monkeypox Study In Journal Of Virology, Peer-Reviewed Publication Of ASM Mt Newswire · July 13, 2026Tonix Pharmaceuticals Reaches Medicare Coverage Deal for Fibromyalgia Treatment Benzinga · July 13, 2026Tonix Secures Medicare Coverage For Fibromyalgia Drug TONMYA, Expands TONMYA Coverage To 145M Lives By 2027 Mt Newswire · June 29, 2026Tonix Pharmaceuticals Advances TNX-102 SL Into Phase 2 MDD Study Mt Newswire · June 25, 2026Raymond James Initiates Coverage on Tonix Pharmaceuticals With Strong Buy Rating, $26 PT Benzinga · June 25, 2026Raymond James Initiates Coverage On Tonix Pharmaceuticals with Strong Buy Rating, Announces Price Target of $26 Benzinga · June 8, 2026Tonix Shares Jump After Landing Second Commercial Payer Agreement For TONMYA Mt Newswire · June 8, 2026Tonix Pharmaceuticals Enters Second Commercial Payer Deal, Expands Drug Coverage